{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T03:09:22Z","timestamp":1777432162204,"version":"3.51.4"},"reference-count":45,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006976","name":"Lilly Endowment","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006976","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000133","name":"Agency for Healthcare Research and Quality","doi-asserted-by":"publisher","award":["1 F32 HS028749-01"],"award-info":[{"award-number":["1 F32 HS028749-01"]}],"id":[{"id":"10.13039\/100000133","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R25 CA 90720"],"award-info":[{"award-number":["R25 CA 90720"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacpajpe.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Pharmaceutical Education"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.ajpe.2023.100061","type":"journal-article","created":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T00:37:35Z","timestamp":1682469455000},"page":"100061","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Opioid Use Disorder Curricular Content in US-Based Doctor of Pharmacy Programs"],"prefix":"10.1016","volume":"87","author":[{"given":"Molly A.","family":"Nichols","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth G.","family":"Riley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander S.","family":"Chao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmina G.","family":"Sales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica L.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geoffrey M.","family":"Curran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol A.","family":"Ott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margie E.","family":"Snyder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen Suchanek","family":"Hudmon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajpe.2023.100061_bib1","unstructured":"Opioid data analysis and resources. Updated June 1, 2022. Centers for Disease Control and Prevention. Accessed October 11, 2022. \u3008https:\/\/www.cdc.gov\/opioids\/data\/analysis-resources.html\u3009."},{"key":"10.1016\/j.ajpe.2023.100061_bib2","unstructured":"US overdose deaths in 2021 increased half as much as in 2020 \u2013 but are still up 15%. Published May 11, 2022. Centers for Disease Control and Prevention. Accessed October 11, 2022. \u3008https:\/\/www.cdc.gov\/nchs\/pressroom\/nchs_press_releases\/2022\/202205.htm\u3009."},{"key":"10.1016\/j.ajpe.2023.100061_bib3","unstructured":"Long K, Manz J.\u00a0Strengthening workforce capacity: state actions to address opioid use disorder during COVID-19. Published May 18, 2020. National Academy for state health policy. Accessed October 11, 2022. \u3008https:\/\/www.nashp.org\/strengthening-workforce-capacity-state-actions-to-address-opioid-use-disorder-during-covid-19\/\u3009."},{"key":"10.1016\/j.ajpe.2023.100061_bib4","unstructured":"Pharmacists: on the front lines \u2013 addressing prescription opioid abuse and overdose. Published October 17, 2016. Centers for Disease Control and Prevention. Accessed October 11, 2022. \u3008https:\/\/stacks.cdc.gov\/view\/cdc\/43485\u3009."},{"issue":"1","key":"10.1016\/j.ajpe.2023.100061_bib5","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13722-019-0158-0","article-title":"Leveraging the role of community pharmacists in the prevention, surveillance, and treatment of opioid use disorders","volume":"14","author":"Bach","year":"2019","journal-title":"Addict Sci Clin Pract"},{"issue":"2","key":"10.1016\/j.ajpe.2023.100061_bib6","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3390\/pharmacy7020060","article-title":"Pharmacist services in the opioid crisis: current practices and scope in the United States","volume":"7","author":"Thakur","year":"2019","journal-title":"Pharmacy"},{"issue":"3","key":"10.1016\/j.ajpe.2023.100061_bib7","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1080\/02791072.2006.10399848","article-title":"Knowledge, attitudes and practices of pharmacists concerning prescription drug abuse","volume":"38","author":"Lafferty","year":"2006","journal-title":"J Psychoactive Drugs"},{"key":"10.1016\/j.ajpe.2023.100061_bib8","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jsat.2014.11.006","article-title":"Factors associated with provision of addiction treatment information by community pharmacists","volume":"52","author":"Hagemeier","year":"2015","journal-title":"J Subst Abuse Treat"},{"issue":"2S","key":"10.1016\/j.ajpe.2023.100061_bib9","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.japh.2016.12.064","article-title":"Pharmacists\u2019 role in opioid overdose: Kentucky pharmacists\u2019 willingness to participate in naloxone dispensing","volume":"57","author":"Freeman","year":"2017","journal-title":"J Am Pharm Assoc"},{"issue":"3","key":"10.1016\/j.ajpe.2023.100061_bib10","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1177\/1059601118756554","article-title":"Transforming health care one team at a time: ten observations and the trail ahead","volume":"43","author":"Salas","year":"2018","journal-title":"Group Organ Manag"},{"issue":"3S","key":"10.1016\/j.ajpe.2023.100061_bib11","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.japh.2020.01.001","article-title":"Indiana community pharmacist preceptors\u2019 knowledge and perceptions of medication-assisted treatment","volume":"60","author":"Davenport","year":"2020","journal-title":"J Am Pharm Assoc"},{"issue":"10","key":"10.1016\/j.ajpe.2023.100061_bib12","doi-asserted-by":"crossref","first-page":"ajpe8001","DOI":"10.5688\/ajpe8001","article-title":"Opioid-related education provided by continuing education divisions at US pharmacy schools","volume":"84","author":"Renfro","year":"2020","journal-title":"Am J Pharm Educ"},{"issue":"1","key":"10.1016\/j.ajpe.2023.100061_bib13","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3390\/pharmacy7010011","article-title":"Readiness of pharmacists based in Utah about pain management and opioid dispensing","volume":"7","author":"Balough","year":"2019","journal-title":"Pharmacy ((Basel))"},{"issue":"1","key":"10.1016\/j.ajpe.2023.100061_bib14","first-page":"1682","article-title":"Differences between pharmacists\u2019 perception of counseling and practice in the era of prescription drug misuse","volume":"18","author":"Thornton","year":"2020","journal-title":"Pharm Pract"},{"issue":"4","key":"10.1016\/j.ajpe.2023.100061_bib15","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1080\/08897077.2019.1616349","article-title":"Pharmacists\u2019 attitudes toward dispensing naloxone and medications for opioid use disorder: a scoping review of the literature","volume":"40","author":"Muzyk","year":"2019","journal-title":"Subst Abus"},{"issue":"5","key":"10.1016\/j.ajpe.2023.100061_bib16","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1177\/0897190010379710","article-title":"Pharmacist\u2019s role in dispensing opioids for acute and chronic pain","volume":"25","author":"Marlowe","year":"2012","journal-title":"J Pharm Pract"},{"issue":"9","key":"10.1016\/j.ajpe.2023.100061_bib17","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/pm\/pnx139","article-title":"Pharmacists\u2019 role in opioid safety: a focus group investigation","volume":"19","author":"Hartung","year":"2018","journal-title":"Pain Med"},{"issue":"2S","key":"10.1016\/j.ajpe.2023.100061_bib18","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/j.japh.2017.01.013","article-title":"Perpetuating stigma or reducing risk? Perspectives from naloxone consumers and pharmacists on pharmacy-based naloxone in 2 states","volume":"57","author":"Green","year":"2017","journal-title":"J Am Pharm Assoc"},{"issue":"1","key":"10.1016\/j.ajpe.2023.100061_bib19","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.japh.2019.06.016","article-title":"Pharmacist roles, training, and perceived barriers in naloxone dispensing: a systematic review","volume":"60","author":"Thakur","year":"2020","journal-title":"J Am Pharm Assoc ((2003))"},{"issue":"8","key":"10.1016\/j.ajpe.2023.100061_bib20","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.sapharm.2019.01.002","article-title":"Pharmacist utilization of prescription opioid misuse interventions: acceptability among pharmacists and patients","volume":"15","author":"Riley","year":"2019","journal-title":"Res Social Adm Pharm"},{"issue":"9","key":"10.1016\/j.ajpe.2023.100061_bib21","doi-asserted-by":"crossref","first-page":"761","DOI":"10.3109\/10826084.2013.787101","article-title":"Prescription drug abuse: a comparison of prescriber and pharmacist perspectives","volume":"48","author":"Hagemeier","year":"2013","journal-title":"Subst Use Misuse"},{"issue":"2","key":"10.1016\/j.ajpe.2023.100061_bib22","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jac5.1178","article-title":"Update to the American College of Clinical Pharmacy pharmacotherapy didactic curriculum toolkit","volume":"3","author":"Flannery","year":"2019","journal-title":"J Am Coll Clin Pharm"},{"key":"10.1016\/j.ajpe.2023.100061_bib23","unstructured":"Curricular guidelines for pharmacy: substance abuse and addictive disease. American Association of Colleges of Pharmacy. Accessed October 11, 2022. \u3008https:\/\/www.aacp.org\/sites\/default\/files\/Curricular%20Guidelines%20for%20Pharmacy%20-%20Substance%20Abuse%20and%20Addictive%20Disease.pdf\u3009."},{"issue":"7","key":"10.1016\/j.ajpe.2023.100061_bib24","doi-asserted-by":"crossref","first-page":"5925","DOI":"10.5688\/ajpe8175925","article-title":"Curriculum in psychiatry and neurology for pharmacy programs","volume":"81","author":"Dopheide","year":"2017","journal-title":"Am J Pharm Educ"},{"issue":"1","key":"10.1016\/j.ajpe.2023.100061_bib25","doi-asserted-by":"crossref","first-page":"14","DOI":"10.9740\/mhc.2018.01.014","article-title":"Surveys of substance use disorders education in US pharmacy programs","volume":"8","author":"Thomas","year":"2018","journal-title":"Ment Health Clin"},{"issue":"1","key":"10.1016\/j.ajpe.2023.100061_bib26","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/S0002-9459(24)03170-X","article-title":"Mental health and psychiatric pharmacy instruction in US colleges and schools of pharmacy","volume":"71","author":"Cates","year":"2007","journal-title":"Am J Pharm Educ"},{"issue":"2\u20133","key":"10.1016\/j.ajpe.2023.100061_bib27","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.healthpol.2011.10.012","article-title":"Health workers at the core of the health system: framework and research issues","volume":"105","author":"Anand","year":"2012","journal-title":"Health Policy"},{"key":"10.1016\/j.ajpe.2023.100061_bib28","unstructured":"Programs by status. American Council for Pharmacy Education. Accessed October 11, 2022. \u3008https:\/\/www.acpe-accredit.org\/accredited-programs-by-status\/\u3009."},{"issue":"2","key":"10.1016\/j.ajpe.2023.100061_bib29","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/14622200500055392","article-title":"Tobacco education in U.S. schools of pharmacy","volume":"7","author":"Hudmon","year":"2005","journal-title":"Nicotine Tob Res"},{"key":"10.1016\/j.ajpe.2023.100061_bib30","unstructured":"Nichols MA. PharmD OUD content curricular survey. Published October 18, 2022. Google drive. Accessed October 18, 2022. \u3008https:\/\/docs.google.com\/document\/d\/17OqW8HPXIDMFQlLaldjuuzIwoYRmlJWW\/edit?usp=sharing&ouid=104373735603598110211&rtpof=true&sd=true\u3009."},{"key":"10.1016\/j.ajpe.2023.100061_bib31","unstructured":"American Association of Colleges of Pharmacy. Profile of Pharmacy Students, Fall 2020. May 2021. Accessed October 11, 2022. https:\/\/www.aacp.org\/research\/institutional-research\/student-applications-enrollments-and-degrees-conferred."},{"issue":"2","key":"10.1016\/j.ajpe.2023.100061_bib32","first-page":"41","article-title":"Mental health stigma: society, individuals, and the profession","volume":"8","author":"Ahmedani","year":"2011","journal-title":"J Soc Work Values Ethics"},{"issue":"1\u20132","key":"10.1016\/j.ajpe.2023.100061_bib33","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.drugalcdep.2013.02.018","article-title":"Stigma among health professionals towards patients with substance use disorders and its consequences for healthcare delivery: systematic review","volume":"131","author":"Van Boekel","year":"2013","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"10.1016\/j.ajpe.2023.100061_bib34","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1080\/08897077.2017.1341448","article-title":"Substance use education in US schools of pharmacy: a systematic review of the literature","volume":"38","author":"Muzyk","year":"2017","journal-title":"Subst Abus"},{"issue":"4","key":"10.1016\/j.ajpe.2023.100061_bib35","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/j.japh.2020.01.021","article-title":"Impact of elective on students\u2019 perceptions of treating patients with a substance use disorder","volume":"60","author":"Jarvi","year":"2020","journal-title":"J Am Pharm Assoc"},{"issue":"6","key":"10.1016\/j.ajpe.2023.100061_bib36","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.cptl.2021.01.029","article-title":"Impact of a psychiatry elective on mental health stigma among pharmacy students","volume":"13","author":"Pepa","year":"2021","journal-title":"Curr Pharm Teach Learn"},{"issue":"4","key":"10.1016\/j.ajpe.2023.100061_bib37","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1080\/08897077.2019.1694618","article-title":"Pharmacy: addressing substance use in the 21st century","volume":"40","author":"Bratberg","year":"2019","journal-title":"Subst Abus"},{"key":"10.1016\/j.ajpe.2023.100061_bib38","unstructured":"Rx for Change: Clinician-Assisted Tobacco Cessation. Regents of the University of California. Accessed October 11, 2022. \u3008https:\/\/rxforchange.ucsf.edu\/\u3009."},{"issue":"4","key":"10.1016\/j.ajpe.2023.100061_bib39","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2217\/pgs.14.181","article-title":"Evaluation of a shared pharmacogenomics curriculum for pharmacy students","volume":"16","author":"Lee","year":"2015","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.ajpe.2023.100061_bib40","unstructured":"Project Share Curriculum: about the Curriculum. Updated July 1, 2020. University of Maryland health sciences and human services library. Accessed October 11, 2022. \u3008https:\/\/guides.hshsl.umaryland.edu\/c.php?g=76220&p=1538472\u3009."},{"issue":"3","key":"10.1016\/j.ajpe.2023.100061_bib41","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1207\/S15430154JCE1803_07","article-title":"Development and implementation of a tobacco cessation training program for students in the health professions","volume":"18","author":"Hudmon","year":"2003","journal-title":"J Cancer Educ"},{"issue":"5","key":"10.1016\/j.ajpe.2023.100061_bib42","doi-asserted-by":"crossref","first-page":"93","DOI":"10.5688\/ajpe77593","article-title":"The role of academic pharmacy in tobacco cessation and control","volume":"77","author":"McBane","year":"2013","journal-title":"Am J Pharm Educ"},{"issue":"12","key":"10.1016\/j.ajpe.2023.100061_bib43","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/j.sapharm.2019.01.005","article-title":"Faculty perceptions of a tobacco cessation train-the-trainer workshop and experiences with implementation: a qualitative follow-up study","volume":"15","author":"Elkhadragy","year":"2019","journal-title":"Res Social Adm Pharm"},{"issue":"9","key":"10.1016\/j.ajpe.2023.100061_bib44","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1016\/j.sapharm.2020.11.018","article-title":"Long-term evaluation of a train-the-trainer workshop for pharmacy faculty using the RE-AIM framework","volume":"17","author":"Elkhadragy","year":"2021","journal-title":"Res Social Adm Pharm"},{"issue":"2","key":"10.1016\/j.ajpe.2023.100061_bib45","doi-asserted-by":"crossref","DOI":"10.2196\/20704","article-title":"Shared tobacco cessation curriculum website for health professionals: longitudinal analysis of user and utilization data over a period of 15 years","volume":"7","author":"Elkhadragy","year":"2021","journal-title":"JMIR Med Educ"}],"container-title":["American Journal of Pharmaceutical Education"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002945923000621?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002945923000621?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:47:13Z","timestamp":1777376833000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002945923000621"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S0002945923000621"],"URL":"https:\/\/doi.org\/10.1016\/j.ajpe.2023.100061","relation":{},"ISSN":["0002-9459"],"issn-type":[{"value":"0002-9459","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Opioid Use Disorder Curricular Content in US-Based Doctor of Pharmacy Programs","name":"articletitle","label":"Article Title"},{"value":"American Journal of Pharmaceutical Education","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajpe.2023.100061","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 American Association of Colleges of Pharmacy. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100061"}}